Cargando…

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease

BACKGROUND: Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by neuropathologic changes involving beta-amyloid (Aβ), tau, neuronal loss, and other associated biological events. While levels of cerebrospinal fluid (CSF) Aβ and tau peptides have enhanced the antemortem de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gangishetti, Umesh, Christina Howell, J., Perrin, Richard J., Louneva, Natalia, Watts, Kelly D., Kollhoff, Alexander, Grossman, Murray, Wolk, David A., Shaw, Leslie M., Morris, John C., Trojanowski, John Q., Fagan, Anne M., Arnold, Steven E., Hu, William T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156847/ https://www.ncbi.nlm.nih.gov/pubmed/30253800 http://dx.doi.org/10.1186/s13195-018-0426-3

Ejemplares similares

Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
por: Patel, Sunil, et al.
Publicado: (2012)

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
por: Toledo, Jon B, et al.
Publicado: (2013)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF
por: Kollhoff, Alexander L., et al.
Publicado: (2018)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease
por: Trombetta, Bianca A., et al.
Publicado: (2018)

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency
por: Rahhal, Samar, et al.
Publicado: (2023)

Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology
por: Sandelius, Åsa, et al.
Publicado: (2018)

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
por: Maxwell, Taylor J., et al.
Publicado: (2018)

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
por: Irwin, David J., et al.
Publicado: (2013)

Plasma phosphorylated tau181 predicts cognitive and functional decline
por: Tropea, Thomas F., et al.
Publicado: (2022)

Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment
por: Garrett, Stephanie L., et al.
Publicado: (2019)

A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias
por: Said, Harun Muayad, et al.
Publicado: (2022)

Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
por: Trojanowski, John Q
Publicado: (2013)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
por: Fagan, Anne M, et al.
Publicado: (2009)

Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
por: Gibbons, Garrett S., et al.
Publicado: (2019)

Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
por: Chen, Charles D., et al.
Publicado: (2023)

Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
por: Kang, Ju-Hee, et al.
Publicado: (2014)

CSF Cytokines in Aging, Multiple Sclerosis, and Dementia
por: Hu, William T., et al.
Publicado: (2019)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment
por: Toledo, Jon B, et al.
Publicado: (2014)

Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals
por: Paterson, R W, et al.
Publicado: (2014)

ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease
por: Ko, Yi-An, et al.
Publicado: (2022)

Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers
por: Howell, Jennifer C., et al.
Publicado: (2017)

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
por: Risacher, Shannon L., et al.
Publicado: (2019)

Preoperative cerebrospinal fluid β-Amyloid/Tau ratio and postoperative delirium
por: Xie, Zhongcong, et al.
Publicado: (2014)

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
por: Dolatshahi, Mahsa, et al.
Publicado: (2018)

Tau pathology associates with in vivo cortical thinning in Lewy body disorders
por: Spotorno, Nicola, et al.
Publicado: (2020)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease
por: Ibanez, Laura, et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology
por: Portelius, Erik, et al.
Publicado: (2018)

Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid
por: Voyle, Nicola, et al.
Publicado: (2016)

Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation
por: Ewers, Michael, et al.
Publicado: (2020)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)

Tau immunotherapy is associated with glial responses in FTLD-tau
por: Kim, Boram, et al.
Publicado: (2021)

Phenylindanes in Brewed Coffee Inhibit Amyloid-Beta and Tau Aggregation
por: Mancini, Ross S., et al.
Publicado: (2018)

Mitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology
por: Esteras, Noemi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_go2bf4u3np6rgi2p647s8f876t